Schmidt Julie A, Allen Naomi E, Almquist Martin, Franceschi Silvia, Rinaldi Sabina, Tipper Sarah J, Tsilidis Konstantinos K, Weiderpass Elisabete, Overvad Kim, Tjønneland Anne, Boutron-Ruault Marie-Christine, Dossus Laure, Mesrine Sylvie, Kaaks Rudolf, Lukanova Annekatrin, Boeing Heiner, Lagiou Pagona, Trichopoulos Dimitrios, Trichopoulou Antonia, Palli Domenico, Krogh Vittorio, Panico Salvatore, Tumino Rosario, Zanetti Roberto, Bueno-de-Mesquita H Bas, Peeters Petra H, Lund Eiliv, Menéndez Virginia, Agudo Antonio, Sánchez María-José, Chirlaque Maria-Dolores, Ardanaz Eva, Larrañaga Nerea, Hennings Joakim, Sandström Maria, Khaw Kay-Tee, Wareham Nick, Romieu Isabelle, Gunter Marc J, Riboli Elio, Key Timothy J, Travis Ruth C
Authors' Affiliations: Cancer Epidemiology Unit; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford; The School of Public Health; Department of Epidemiology and Biotatistics, School of Public Health, Imperial College London, London; Department of Public Health and Primary Care; MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom; Department of Surgery, Lund University Hospital, Lund; Malmö Diet and Cancer Study, Lund University, Malmö; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm; Departments of Medical Biosciences, Pathology; Surgical and Perioperative Science; and Radiation Sciences, Oncology, Umeå University, Umeå, Sweden; International Agency for Research on Cancer, Lyon; Inserm, Centre for Research in Epidemiology and Population Health (CESP), U1018, Nutrition, Hormones and Women's Health Team; Université Paris Sud, UMRS 1018; Institut Gustave Roussy, Villejuif, France; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina; WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School; Bureau of Epidemiologic Research, Academy of Athens; Hellenic Health Foundation, Athens, Greece; Department of Community Medicine, UiT The Norwegian Arctic University, Tromsø; Department of Research, Cancer Registry of Norway, Oslo, Norway; Samfundet Folkhälsan, Helsinki, Finland; Section for Epidemiology, Department of Public Health, Aarhus University, Aarhus; Diet, Genes, and Environment, Danish Cancer Society Research Center, Copenhagen Ø, Denmark; Hormones and Cancer Group; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg; Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany; Department of Epidemiology, Harvard School of Pu
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):976-85. doi: 10.1158/1055-9965.EPI-13-1210-T. Epub 2014 Mar 19.
Little is known about the causes of thyroid cancer, but insulin-like growth factor-I (IGF-I) might play an important role in its development due to its mitogenic and antiapoptotic properties.
This study prospectively investigated the association between serum IGF-I concentrations and risk of differentiated thyroid carcinoma in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. The 345 incident cases of differentiated thyroid carcinoma were individually matched to 735 controls by study center, sex and age, date, time, and fasting status at blood collection, follow-up duration, and for women menopausal status, use of exogenous hormones, and phase of menstrual cycle at blood collection. Serum IGF-I concentrations were measured by immunoassay, and risk of differentiated thyroid cancer in relation to IGF-I concentration was estimated using conditional logistic regression.
There was a positive association between IGF-I concentrations and risk of differentiated thyroid carcinoma: the OR for a doubling in IGF-I concentration was 1.48 (95% confidence interval, 1.06-2.08; Ptrend = 0.02). The positive association with IGF-I was stable over time between blood collection and cancer diagnosis.
These findings suggest that IGF-I concentrations may be positively associated with risk of differentiated thyroid carcinoma.
This study provides the first prospective evidence of a potential association between circulating IGF-I concentrations and risk of differentiated thyroid carcinoma and may prompt the further investigations needed to confirm the association.
甲状腺癌的病因鲜为人知,但胰岛素样生长因子-I(IGF-I)因其促有丝分裂和抗凋亡特性,可能在其发展过程中发挥重要作用。
在欧洲癌症与营养前瞻性调查(European Prospective Investigation into Cancer and Nutrition)中的一项病例对照研究中,前瞻性地调查血清IGF-I浓度与分化型甲状腺癌风险之间的关联。345例分化型甲状腺癌新发病例按研究中心、性别、年龄、采血日期、时间、空腹状态、随访时间进行个体匹配,女性还按绝经状态、外源性激素使用情况及采血时的月经周期阶段与735名对照进行匹配。采用免疫分析法测定血清IGF-I浓度,并使用条件逻辑回归估计与IGF-I浓度相关的分化型甲状腺癌风险。
IGF-I浓度与分化型甲状腺癌风险呈正相关:IGF-I浓度翻倍的比值比为1.48(95%置信区间为1.06 - 2.08;P趋势 = 0.02)。从采血到癌症诊断期间,与IGF-I的正相关关系随时间保持稳定。
这些发现表明IGF-I浓度可能与分化型甲状腺癌风险呈正相关。
本研究首次提供了循环IGF-I浓度与分化型甲状腺癌风险之间潜在关联的前瞻性证据,可能促使开展进一步研究以证实这种关联。